🇺🇸 FDA
Pipeline program

Carbetocin Nasal Spray, Placebo to match carbetocin 11.4 mg/ml (2ml /vial)

ACP-101-302

Phase 3 small_molecule active

Quick answer

Carbetocin Nasal Spray, Placebo to match carbetocin 11.4 mg/ml (2ml /vial) for Hyperphagia related behaviour associated with Prader-Willi Syndrome (PWS) is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Hyperphagia related behaviour associated with Prader-Willi Syndrome (PWS)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials